An Open, Multi-center, Phase II Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Fuzuloparib (Primary) ; Abiraterone acetate; Enzalutamide; Prednisone acetate; Rivoceranib
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 23 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2021 Status changed from not yet recruiting to recruiting.
- 06 May 2021 New trial record